On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Next generation sequencing technologies (NGS) such as whole genome, whole exome, and large panels of genes, are rapidly changing the paradigm of medicine. Widespread use of NGS carries with it many ethical and practical challenges, some of which persist despite considerable debate. Whether laboratories and clinics should report variants of uncertain significance (VUS) to clinicians and/or patients, reinterpret VUS in response to the growing knowledge in the field, reissue reports to clinicians based on any revised classifications, and recontact patients, are all key unsolved issues in the clinical use of NGS. In addition, the question of whether, and to what extent, unsolicited findings (also known as incidental findings) should be returned to patients following NGS remains unanswered. In this presentation, Danya will discuss these issues, drawing on data from a systematic analysis 58 consent forms being used in the diagnostic setting to investigate their policies.
